このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

腎性シスチン症の小児の参加者におけるDFT383 (CYStem)

2026年10月15日 更新者:Novartis Pharmaceuticals

腎性シスチン症の小児参加者におけるDFT383の安全性、忍容性、有効性を評価するためのオープンラベル、マルチセンター、フェーズI/II研究

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.

The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.

This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.

調査の概要

状態

募集

介入・治療

詳細な説明

This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.

The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.

Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.

The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.

Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.

Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Novartis Pharmaceuticals

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85016
        • 募集
        • Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
        • コンタクト:
        • 主任研究者:
          • Shanna White
    • California
      • San Diego、California、アメリカ、92123
        • 募集
        • University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
        • コンタクト:
        • 主任研究者:
          • Nadine Benador nbenador@health.ucsd.edu
      • Stanford、California、アメリカ、94305
        • 募集
        • Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
        • 主任研究者:
          • Alice Bertaina
        • コンタクト:
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
        • 主任研究者:
          • Laurence (Larry) Greenbaum
        • コンタクト:
          • Laurence (Larry) Greenbaum
          • 電話番号:404-712-6374
          • メール:lgreen6@emory.edu
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • Children's Hospital of Philadelphia (Recruiting Cohort 0)
        • コンタクト:
          • Melissa Cadnapaphornchai
          • 電話番号:215-590-2449
        • 主任研究者:
          • Melissa Cadnapaphornchai
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
        • コンタクト:
        • 主任研究者:
          • Ewa Elenberg

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~5年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all the following criteria:

  1. Informed consent in writing from parent(s) or legal guardian(s) must be provided
  2. 2 to 5 years of age (including 5 years and 364 days old) at Screening
  3. Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
  4. Oral cysteamine therapy for at least 6 months
  5. Historic clinical diagnosis of nephropathic cystinosis
  6. Laboratory evidence of of renal fanconi syndrome (RFS)
  7. Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
  8. Received all age-appropriate vaccinations

Key exclusion Criteria for Cohort 1 and 0

  1. A history of kidney transplantation
  2. A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
  3. History of malignancy
  4. A severe or uncontrolled medical disorder
  5. Major surgery within 90 days

Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:

1. Indomethacin within 2 weeks prior to Screening

Other protocol-defined inclusion/exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1 (DFT383)

Treatment with DFT383

DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.

介入なし:Cohort 0 (SoC)

No study treatment, will continue with standard of care (cysteamine).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Core Phase - Incidence of adverse events (Cohort 1)
時間枠:Up to 32 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 32 months
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
時間枠:42 days post DFT infusion

Hematological reconstitution by Day 42 post-DFT383 infusion

42 days post DFT infusion
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
時間枠:Up to 32 months

Proportion of participants with reversal of renal Fanconi syndrome (RFS)

Up to 32 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Core Phase - Number of participants independent from cysteamine
時間枠:up to 24 months

Independence from oral and ophthalmic cysteamine

up to 24 months
Core Phase - Health-related quality of life (HRQOL)
時間枠:Up to 32 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 32 months
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
時間枠:Up to 24 months

Time from infusion to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Time from screening to reversal of RFS (Cohort 0)
時間枠:Up to 24 months

Time from screening to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Duration of reversal of RFS
時間枠:Up to 24 months

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
時間枠:Up to 27 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 27 months
Core Phase - Change from baseline on urine amino acids
時間枠:Up to 27 months

Change from baseline on urine amino acids

Up to 27 months
Core Phase - Change from baseline on urinary glucose to creatinine ratio
時間枠:Up to 27 months

Change from baseline on urinary glucose to creatinine ratio

Up to 27 months
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
時間枠:Up to 27 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 27 months
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
時間枠:Up to 27 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 27 months
Core Phase - Number of participants with improvement of proximal tubular function
時間枠:Up to 27 months

Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization.

Up to 27 months
Core Phase - Corneal cystine crystal content
時間枠:Up to 27 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 27 months
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
時間枠:Up to 27 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 27 months
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
時間枠:Up to 27 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 27 months
Core Phase - Number of participants with malignancy (Cohort 1)
時間枠:Up to 27 months

Number of participants with malignancy

Up to 27 months
Core Phase - Time to hematological reconstitution (Cohort 1)
時間枠:Up to 24 months

Time to hematological reconstitution

Up to 24 months
Core Phase - Time to platelet engraftment (Cohort 1)
時間枠:Up to 24 months

Time to platelet engraftment

Up to 24 months
Core Phase - Incidence of Adverse Events (Cohort 0)
時間枠:up to 24 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

up to 24 months
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
時間枠:Up to 15 years and 8 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 15 years and 8 months
Extension Phase - Number of participants with malignancy (Cohort 1)
時間枠:Up to 15 years and 3 months

Number of participants with malignancy

Up to 15 years and 3 months
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
時間枠:Up to 15 years and 3 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 15 years and 3 months
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
時間枠:Up to 15 years and 3 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
時間枠:Up to 15 years and 3 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
時間枠:Up to 15 years and 3 months

Change from baseline on urine amino acids

Up to 15 years and 3 months
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
時間枠:Up to 15 years and 3 months

Change from baseline on urinary glucose to creatinine ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
時間枠:Up to 15 years and 3 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
時間枠:Up to 15 years and 3 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 15 years and 3 months
Extension Phase - Duration of reversal of RFS (Cohort 1)
時間枠:Up to 15 years

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 15 years
Extension Phase - Number of participants with kidney failure (Cohort 1)
時間枠:Up to 15 years

Number of participants with kidney failure

Up to 15 years
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
時間枠:Up to 15 years

Independence from oral and ophthalmic cysteamine

Up to 15 years
Extension Phase - Corneal cystine crystal content (Cohort 1)
時間枠:Up to 15 years and 3 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 15 years and 3 months
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
時間枠:Up to 15 years and 8 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 15 years and 8 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月2日

一次修了 (推定)

2031年5月28日

研究の完了 (推定)

2044年5月28日

試験登録日

最初に提出

2025年3月17日

QC基準を満たした最初の提出物

2025年3月27日

最初の投稿 (実際)

2025年4月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月16日

QC基準を満たした最後の更新が送信されました

2026年10月15日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する